Finally, a study presented at the 2024 ASCO GU conference investigated the role of kidney injury molecule-1 (KIM-1) as a potential biomarker for patients with localized RCC at high risk for recurrence post-nephrectomy who may benefit from adjuvant atezolizumab treatment [174]. The gene discussed is HAVCR1; the disease is renal cell carcinoma.